Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
TCR2 THERAPEUTICS INC. (TCRR)
|
Add to portfolio |
|
|
|
| Price: |
$4.53
| | Metrics |
| OS: |
39.3
|
M
| |
|
|
| Market cap: |
$178
|
M
| |
-185
|
% ROIC
|
|
Net cash:
|
$110
|
M
| |
$2.81
|
per share
|
|
EV:
|
$67.5
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($164)
|
M
| |
|
|
|
EBIT
|
($167)
|
M
| |
|
|
| EPS |
($4.16)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 0.0 | 98.6 | 0.0 | 73.6 | 0.0 | 0.0 | 0.0 | 9.6 |
| Revenue growth | | 34.1% | | | | | -100.0% | 24.5% |
| Cost of goods sold | 0.0 | 153.5 | 0.0 | 99.7 | 0.0 | 0.0 | 0.0 | 13.2 |
| Gross profit | 0.0 | -54.9 | 0.0 | -26.2 | 0.0 | 0.0 | 0.0 | -3.6 |
| Gross margin | | -55.6% | | -35.6% | | | | -37.7% |
| Selling, general and administrative | 153.5 | | 99.7 | | 68.7 | | | |
| Research and development | | | | | | 37.5 | 19.7 | |
| General and administrative | | 24.4 | | 22.5 | | 13.9 | 6.8 | 3.6 |
| EBIT | -119.2 | -153.5 | -95.6 | -99.7 | -65.2 | -51.4 | -26.5 | -13.2 |
| EBIT margin | | -155.6% | | -135.6% | | | | -137.7% |
| Pre-tax income | -151.6 | -151.6 | -99.5 | -99.5 | -67.0 | -47.5 | -24.3 | -13.1 |
| Income taxes | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.1 | 0.0 | 0.0 |
| Tax rate | | | | | | | 0.0% | 0.0% |
| Net income | -151.8 | -151.8 | -99.8 | -99.8 | -67.1 | -97.5 | -61.5 | 0.0 |
| Net margin | | -153.9% | | -135.6% | | | | -0.2% |
| |
| Diluted EPS | ($3.93) | ($3.93) | ($2.63) | ($2.63) | ($2.40) | ($4.62) | ($98.53) | ($39.94) |
| Shares outstanding (diluted) | 38.6 | 38.6 | 37.9 | 37.9 | 28.0 | 21.1 | 0.6 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|